|
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016 open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15 |
Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter
Copyright Infringement Claims
Indexing Partner
|
Published Paper Details
|
|
| Paper Title: | Branded Generic Drugs and Competition |
| Authors Name: | Shrushti Wagh , Aditya Raut , Racheal Palmer |
| Unique Id: | IJSDR2404206 |
| Published In: | Volume 9 Issue 4, April-2024 |
| Abstract: | The pharmaceutical sector is distinguished by a complicated interaction between branded and generic medications. Branded pharmaceuticals manufactured and marketed by pharmaceutical corporations sometimes have exclusivity periods due to patents, allowing them to fetch higher costs. When patents expire, generic rivals join the market and offer comparable drugs at reduced prices. This dynamic fosters fierce rivalry, affecting pricing tactics, market share, and innovation. This research investigates the dynamics of competition between branded and generic medications. It investigates the variables that influence generic market entrance, such as legislative channels and litigation, as well as pharmaceutical corporations' strategy for maintaining market dominance. It also analyses how healthcare policy and regulations shape this competitive landscape. Furthermore, the research explores how branded-generic rivalry affects healthcare accessibility, pricing, and patient welfare. It emphasizes the importance of generic medicine availability in lowering healthcare costs and boosting pharmaceutical accessibility, particularly in poor nations. However, it notes concerns about the quality and safety of generic pharmaceuticals, as well as the possible influence on innovation incentives in the pharmaceutical business. Overall, this article sheds light on the intricacies of branded-generic medication rivalry and its ramifications for stakeholders throughout the healthcare ecosystem, including patients, providers, governments, and pharmaceutical corporations. It emphasizes the significance of combining innovation incentives with the requirement for inexpensive and accessible pharmaceuticals in order to achieve optimal healthcare outcomes for all. |
| Keywords: | Branded generic drug, pharmaceutical industry, drug competition. |
| Cite Article: | "Branded Generic Drugs and Competition", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.9, Issue 4, page no.1408 - 1416, April-2024, Available :http://www.ijsdr.org/papers/IJSDR2404206.pdf |
| Downloads: | 000338173 |
| Publication Details: | Published Paper ID: IJSDR2404206 Registration ID:211119 Published In: Volume 9 Issue 4, April-2024 DOI (Digital Object Identifier): Page No: 1408 - 1416 Publisher: IJSDR | www.ijsdr.org ISSN Number: 2455-2631 |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijsdr.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
Track Paper
Important Links
Conference Proposal
ISSN
 |
 |
DOI (A digital object identifier)
  Providing A digital object identifier by DOI How to GET DOI and Hard Copy Related |
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
 |
 |
 |
Social Media
Indexing Partner |
|||
| Copyright © 2024 - All Rights Reserved - IJSDR | |||
Facebook Twitter Instagram LinkedIn